Improving on PPI-based therapy of GORD

Area of Science:

• Biochemistry
• Pharmacology
• Gastroenterology

Background:

• Proton pump inhibitors (PPIs) are effective treatments for gastro-oesophageal reflux disease (GORD).
• PPIs inhibit the final step of gastric acid secretion by blocking the hydrogen-potassium adenosine triphosphatase (H+,K+-ATPase) pump.
• Current PPI formulations have limitations including slow onset of action and short plasma half-lives due to their mechanism of action.

Purpose of the Study:

• To explore strategies for improving the efficacy of PPIs in treating GORD.
• To address the limitations of current PPIs, focusing on achieving rapid and complete acid secretion inhibition.
• To investigate potential advancements in PPI therapy, including enantiomer-based approaches and pro-drug development.

Main Methods:

• Review of PPI biochemistry and mechanism of action.
• Analysis of clinical data on PPI enantiomers, such as esomeprazole.
• Exploration of pro-drug strategies to extend PPI plasma half-lives.
• Discussion of ongoing research into novel acid-pump antagonists.

Main Results:

• PPIs achieve acid suppression through covalent inhibition of H+,K+-ATPase, leading to prolonged effects after drug elimination.
• Short plasma half-lives and the need for accumulation/activation in parietal cells contribute to a slow onset of action.
• The S-enantiomer of omeprazole (esomeprazole) shows potential for improved acid control.
• Pro-drug development and acid-pump antagonists are promising avenues for enhanced acid secretion inhibition.

Conclusions:

• Optimizing PPI therapy requires overcoming limitations related to onset of action and plasma half-life.
• Exploiting enantiomer metabolism and developing pro-drugs are key strategies for extending PPI efficacy.
• Further research into novel acid-pump antagonists offers alternative approaches to managing acid-related disorders.